Skip to Content

  • Search

View Additional Section Content

CP3R and AMH’s Performance for Breast Cancer

BREAST CONSERVING SURGERY AND RADIATION THERAPY

Breast Conserving Surgery and Radiation Therapy

Radiation therapy is administrated within one year (365 days) of diagnosis for women under the age of 70 receiving breast conserving surgery for breast cancer. Abington Memorial Hospital’s compliance with this standard is favorable at 95.4%, compared to all CoC approved programs’ norm of 91.8%.


CHEMOTHERAPY IN HORMONE RECEPTOR NEGATIVE BREAST CANCER PATIENTS

Chemotherapy in Hormone Receptor Negative Breast Cancer Patients

Combination chemotherapy is considered or administered within four months (120 days) of diagnosis for women under the age of 70 with AJCC T1c N0M0, or Stage II or III hormone receptor negative cancer. Abington Memorial Hospital’s compliance with this standard is favorable at 94.1%, compared to all CoC approved programs’ norm of 92.3%.


TAMOXIFEN OR THIRD GENERATION AROMATASE INHIBITOR IN HORMONE RECEPTOR POSITIVE BREAST CANCER PATIENTS

Tamoxifen or Third Generation Aromatase Inhibitor in Hormone Receptor Positive Breast Cancer Patients

Tamoxifen or third generation aromatase inhibitor is considered or administered within one year (365 days) of diagnosis for women with AJCC T1c N0M0, or Stage II or III hormone receptor positive cancer. Abington Memorial Hospital’s compliance with this standard is favorable at 92.1%, compared to all CoC approved programs’ norm of 89.5%.

How We Compare to the National Cancer Database